SAFETY DATA SHEET



SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

RYTHMOL TABLETS

of the mixture

Registration number

Synonyms RYTHMOL 150 MG TABLETS * RYTHMOL 225 MG TABLETS * RYTHMOL 300 MG TABLETS *

PROPAFENONE HYDROCHLORIDE, FORMULATED PRODUCT

Issue date 01-November-2013

Version number 02

Revision date 01-November-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Medicinal Product

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Uses advised against No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK 980 Great West Road

Brentford, Middlesex TW8 9GS UK

UK General Information (normal business hours): +44-20-8047-5000

Email Address: msds@gsk.com Website: www.gsk.com

1.4. Emergency telephone

number

TRANSPORT EMERGENCIES::

UK In-country toll call: +(44)-870-8200418 International toll call: +1 703 527 3887

available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies.

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Material name: RYTHMOL TABLETS SDS UK **General information**

Chemical name % CAS-No. / EC No. REACH Registration No. INDEX No. Notes

PROPAFENONE HYDROCHLORIDE 72.25 34183-22-7 -

251-867-9

Classification: DSD: Xn;R20/22, Xi;R36/37/38

CLP: Acute Tox. 4;H302

Starch 10 - < 20 9005-25-8 - -

232-679-6

Classification: DSD: -

CLP: -

Polyethylene glycol 1 - < 3 68130-99-4 - -

Classification: DSD: -

CLP: -

MAGNESIUM STEARATE < 1 557-04-0 -

209-150-3

Classification: DSD: Xi;R36/37/38

CLP: Skin Irrit. 2;H315, Eye Irrit. 2;H319, STOT SE 3;H335

Titanium dioxide < 1 13463-67-7 - -

236-675-5

Classification: DSD: -

CLP: -

Other components below reportable levels 3 - < 5

CLP: Regulation No. 1272/2008.

DSD: Directive 67/548/EEC.

M: M-factor

vPvB: very persistent and very bioaccumulative substance.

PBT: persistent, bioaccumulative and toxic substance.

#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves. Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk

assessment.

4.1. Description of first aid measures

In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is

difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get

medical attention if symptoms occur.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Immediately flush eyes with plenty of water for at least 15 minutes. Get medical attention if

irritation develops and persists.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately.

4.2. Most important symptoms and effects, both acute and

delayed

The following adverse effects have been noted with therapeutic use of this material: irregular heartbeat; temporary decrease in white blood cell count; sensation of bitter taste; dizziness;

nausea; vomiting; constipation.

4.3. Indication of any immediate medical attention and special treatment needed

Material name: RYTHMOL TABLETS

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

media

Water spray. Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

None known.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting

procedures

In the event of fire, cool tanks with water spray.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear

appropriate personal protective equipment. Do not touch or walk through spilled material. Avoid inhalation of dust. Ventilate closed spaces before entering them. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the MSDS.

6.2. Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up

Stop the flow of material, if this is without risk. Following product recovery, flush area with water.

6.4. Reference to other

For personal protection, see section 8. For waste disposal, see section 13.

sections

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Minimise dust generation and accumulation. Do not taste or swallow, Avoid breathing dust, Avoid contact with skin. Avoid contact with eyes. Avoid prolonged exposure. Use only outdoors or in a well-ventilated area. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. When using, do not eat, drink or smoke. Wash hands thoroughly after handling.

7.2. Conditions for safe storage, including any incompatibilities

Store locked up. Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store in a well-ventilated place. Store away from incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s)

Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK				
Components	Туре	Value	Note	
MAGNESIUM STEARATE (CAS 557-04-0)	OHC	1		
PROPAFENONE HYDROCHLORIDE (CAS 34183-22-7)	OHC	2	>100 - <=1000 mcg/m3	
UK. EH40 Workplace Exposure Li	mits (WELs)			
Components	Type	Value	Form	
Starch (CAS 9005-25-8)	TWA	4 mg/m3	Respirable.	
		40 / 0	labalabla	

10 mg/m3 Inhalable Titanium dioxide (CAS **TWA** 4 mg/m3 Respirable. 13463-67-7) Inhalable 10 mg/m3

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived No Effect Level (DNEL)

Not available.

Predicted no effect concentrations (PNECs)

Not available.

8.2. Exposure controls

Appropriate engineering

controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level. Ensure adequate ventilation, especially in confined areas.

Individual protection measures, such as personal protective equipment

General information

Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection

If contact is likely, safety glasses with side shields are recommended. (eg. EN 166)

Skin protection

- Hand protection

The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. Select suitable chemical resistant protective gloves (EN

374) with a protective index 6 (>480min permeation time).

- Other Not normally needed.

Respiratory protection No personal respiratory protective equipment normally required. Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures An occupational/industrial hygiene monitoring method has been developed for this material. For

advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional. When using, do not eat, drink or smoke. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

Environmental exposure controls

Hazard guidance and control recommendations Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state Solid. **Form** Tablet.

Colour Not available. Odour Not available. **Odour threshold** Not available. Not available. pН Melting point/freezing point Not available. Initial boiling point and boiling

range

Not available.

Flash point Not available. **Evaporation rate** Not available. Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

Not available. Vapour pressure Vapour density Not available. Not available Relative density Not available. Solubility(ies) **Partition coefficient** Not available.

(n-octanol/water)

Auto-ignition temperature Not available. Not available. **Decomposition temperature** Not available. Viscosity

Material name: RYTHMOL TABLETS

Not available. **Explosive properties** Not available. Oxidizing properties

9.2. Other information No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

10.2. Chemical stability Material is stable under normal conditions.

10.3. Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

10.4. Conditions to avoid Contact with incompatible materials.

10.5. Incompatible materials Acids.

10.6. Hazardous

Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

decomposition products

SECTION 11: Toxicological information

Occupational exposure to the substance or mixture may cause adverse effects. **General information**

Information on likely routes of exposure

Health injuries are not known or expected under normal use. May be harmful if swallowed. Ingestion Health injuries are not known or expected under normal use. Inhalation of dusts may cause Inhalation

respiratory irritation.

Skin contact Health injuries are not known or expected under normal use. Dust or powder may irritate the skin.

Health injuries are not known or expected under normal use. Dust or powder may irritate eye Eye contact

tissue.

The following adverse effects have been noted with therapeutic use of this material: irregular Symptoms

heartbeat; temporary decrease in white blood cell count; sensation of bitter taste; dizziness;

nausea; vomiting; constipation.

11.1. Information on toxicological effects

Acute toxicity May be harmful if swallowed.

Components	Species	Test results
MAGNESIUM STEARATE (CAS 557-04-0)		

Acute

Oral

LD50 Rat > 2000 mg/kg

PROPAFENONE HYDROCHLORIDE (CAS 34183-22-7)

Acute

Oral

Rat 700 mg/kg

Titanium dioxide (CAS 13463-67-7)

Acute

Inhalation

LC50 Rat 6820 mcg/m3

Oral LD50

Rat > 24 g/kg

Chronic

Inhalation

LOEC Rat 8.6 mg/m3, 1 years, TiO2 accumulated in

interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue.

NOAEC Rat 250 mg/m3, 2 years, Highest dose

5 mg/m3, 24 months

Subacute

Inhalation

Material name: RYTHMOL TABLETS

LOEL Rat 0.1 - 35 mg/m3, 4 weeks, Mild macrophage

> hyperplasia, no change in bronchio-alveolar lavage fluid.

NOAEC Guinea pig 26 mg/m3, 3 weeks, No evidence of significant inflammation in respiratory tract.

Components **Species Test results** Oral

NOAEL Rat 100000 ppm, 14 Day, Dietary study,

highest dose tested.

Subchronic

Inhalation

LOEC Rat 3.2 - 20 mg/m3, 8 min, Accumulation of

TiO2 in macrophages and evidence of

pulmonary inflammation.

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Irritation Corrosion - Skin

TITANIUM DIOXIDE Acute dermal irritation; OECD 404, Literature data

> Result: Non-irritant Species: Rabbit Literature data Result: Non-irritant Species: Guinea pig Literature data Result: Non-irritant Species: Human

Irritation Corrosion - Skin: P.I.I. value

MAGNESIUM STEARATE

Serious eye damage/eye irritation

Health injuries are not known or expected under normal use. Dust or powder may irritate eye

tissue.

Eve

TITANIUM DIOXIDE OECD 405, Literature data

> Result: Mild irritant Species: Rabbit

Respiratory sensitisation Not available.

Skin sensitisation Health injuries are not known or expected under normal use.

Sensitisation

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

> Result: negative Species: Guinea pig

Test Duration: 48 hour exposure Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Germ cell mutagenicity

TITANIUM DIOXIDE

Mutagenicity

PROPAFENONE HYDROCHLORIDE Ames Assay, Literature data

Result: negative Ames, Literature data Result: negative

PROPAFENONE HYDROCHLORIDE Chromosomal Aberration Assay In Vitro, human

lymphocytes, Literature data

Result: negative

Chromosomal Aberration Assay In Vivo, bone marrow,

Literature data Result: negative Species: Hamster

Chromosomal Aberration Assay In Vivo, bone marrow,

Literature data Result: negative Species: Rat

Chromosomal Aberration Assay In Vivo; germ cells,

Literature data Result: negative Species: Hamster

Dominant lethal assay, Literature data

Result: negative Species: Mouse

TITANIUM DIOXIDE Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Material name: RYTHMOL TABLETS

Mutagenicity

TITANIUM DIOXIDE Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

Micronucleus Assay, Literature data PROPAFENONE HYDROCHLORIDE

Result: negative Species: Hamster

Micronucleus Assay, Literature data

Result: negative Species: Rat

TITANIUM DIOXIDE Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Result: positive

Health injuries are not known or expected under normal use. This product is not considered to be Carcinogenicity

a carcinogen by IARC, ACGIH, NTP, or OSHA. Contains a material (titanium dioxide) classified as a carcinogen by external agencies. Carcinogenic activity was seen in inhalation studies using laboratory animals. High concentrations or doses administered over an extended period of time

were required to produce adverse effects.

0.5 mg/m3, Literature data TITANIUM DIOXIDE

Result: negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

PROPAFENONE HYDROCHLORIDE 2 year bioassay, Literature data

Result: negative Species: Mouse

2 year bioassay, Literature data

Result: negative Species: Rat

25000 - 50000 ppm, Dietary study TITANIUM DIOXIDE

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

IARC Monographs. Overall Evaluation of Carcinogenicity

Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

Reproductive toxicity This product is not expected to cause reproductive or developmental effects.

Reproductive toxicity

Reproductivity

Embryo-foetal development - Oral, Literature data PROPAFENONE HYDROCHLORIDE

Result: LOAEL (foetal effects) = 15 mg/kg/day (increased

post-implantation loss, no maternal effect)

Species: Rabbit

Embryo-foetal development - Oral, Literature data Result: Maternal and foetal toxicity (no evidence of

malformations) with dose of 150 mg/kg/day

Species: Rabbit

Embryo-foetal development - Oral, Literature data Result: Maternal and foetal toxicity (no evidence of

malformations) with doses of 600 mg/kg/day

Species: Rat

Embryo-foetal development - Oral, Literature data Result: NOAEL (maternal and foetal) = 270 mg/kg/day

Species: Rat

Reproductivity

PROPAFENONE HYDROCHLORIDE Fertility, Literature data

Result: NOAEL (oral) / fertility = 270 mg/kg/day (maximum dose; 3X equivalent of recommended maximum human

therapeutic dose) Species: Rat

Specific target organ toxicity -

single exposure

None known.

Specific target organ toxicity -None known.

repeated exposure

PROPAFENONE HYDROCHLORIDE

Repeat dose non-clinical studies

Result: NOAEL = 90 mg/kg/day (eqivalent to maximum recommended human dose); with doses of 180 mg/kg/day or more for 6 months adverse, but reversible, changes were observed in kidney; with doses of 270 mg/kg/day fatty

degeneration of liver was observed

Species: Rat Organ: kidney, liver

Aspiration hazard

Mixture versus substance

No information available.

information

Not available. Other information

SECTION 12: Ecological information

12.1. Toxicity Not expected to be harmful to aquatic organisms.

Not available.

Components **Species Test results** MAGNESIUM STEARATE (CAS 557-04-0) Aquatic Acute Fish EC50 Orange-red killfish (Adult Oryzias 130 mg/l, 96 hours latipes) Microtox EC50 Microtox 12.5 mg/l, 15 minutes Titanium dioxide (CAS 13463-67-7) Aquatic Acute Crustacea EC50 Water flea (Daphnia magna) > 1000 mg/l, 48 hours, Static test

12.2. Persistence and

degradability

Persistence and degradability

Photolysis

Half-life (Photolysis-atmospheric)

MAGNESIUM STEARATE 17 Hours Estimated

UV/visible spectrum wavelength

MAGNESIUM STEARATE 210 nm

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

MAGNESIUM STEARATE 77 %, 28 days BOD

Percent degradation (Aerobic biodegradation-ready)

MAGNESIUM STEARATE 95 %, 22 days Sturm test

Percent degradation (Aerobic biodegradation-soil)

MAGNESIUM STEARATE 50 %, 13 days

12.3. Bioaccumulative potential

Not available. **Partition coefficient**

n-octanol/water (log Kow)

Bioconcentration factor (BCF)

Material name: RYTHMOL TABLETS

MAGNESIUM STEARATE > 9999 Estimated

12.4. Mobility in soil

^{*} Estimates for product may be based on additional component data not shown.

Adsorption

Soil/sediment sorption - log Koc

MAGNESIUM STEARATE 5.86 Estimated

Not available

12.5. Results of PBT

and vPvB assessment

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

EU waste codeThe Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. This material

and its container must be disposed of as hazardous waste. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international

regulations.

Special precautionsDispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk

according to Annex II of

MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine

environment. These materials may not be transported in bulk.

MARPOL73/78 and the IBC Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Material name: RYTHMOL TABLETS

Restrictions on use

131750 Version No.: 02 Revision date: 01-November-2013 Issue date: 01-November-2013

SDS UK

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations The product is classified and labelled in accordance with EC directives or respective national laws.

This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.

National regulations 15.2. Chemical safety Follow national regulation for work with chemical agents. No Chemical Safety Assessment has been carried out.

assessment

SECTION 16: Other information

List of abbreviations Not available

GSK Hazard Determination References

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.

Full text of any statements or R-phrases and H-statements

under Sections 2 to 15 R20/22 Harmful by inhalation and if swallowed.

R36/37/38 Irritating to eyes, respiratory system and skin.

H302 Harmful if swallowed. H315 Causes skin irritation. H319 Causes serious eye irritation. H335 May cause respiratory irritation.

Revision information Product and Company Identification: Business Units

Composition / Information on Ingredients: Ingredients

Transport Information: Agency Name and Packaging Type/Transport Mode Selection

Regulatory Information: United States

GHS: Classification

Training information Follow training instructions when handling this material.

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Material name: RYTHMOL TABLETS

SDS UK 10 / 10 131750 Version No.: 02 Revision date: 01-November-2013 Issue date: 01-November-2013